Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 58

Sort by

Sort Order Select

Journal Articles

Aberrant Cell Cycle Programming Confers Rapid Lethality in the EuSOX11+ CCND1 MCL Mouse Model

Donna R Edwards, MPH, PhD, Pei-yu Kuo, MS, Alessandro Lagana, PhD, Seongjee Park, Pavithra Nedumaran, MS, Violetta Leshchenko, PhD, Stephanie Christie, PhD, Shashidhar Jatiani, PhD, Julie Teruya-Feldstein, MD, Samir Parekh, MD

Blood (2020) 136 (Supplement 1): 6–7.

https://doi.org/10.1182/blood-2020-143038

Published: 2020

Journal Articles

28-Day Metronomic Therapy for Relapsed Refractory Multiple Myeloma

Tarek H Mouhieddine, MD, Julia Hieulle, Erin Moshier, MS, Josh R. Richter, MD, Hearn Jay Cho, MD PhD, Samir Parekh, MD, Ajai Chari, MD, Bart Barlogie, MD PhD, Sundar Jagannath, MD, Deepu Madduri, MD

Blood (2020) 136 (Supplement 1): 13.

https://doi.org/10.1182/blood-2020-142210

Published: 2020

Journal Articles

Effect of Intravenous Immunoglobulin on Infections in Multiple Myeloma (MM) Patients Receiving Daratumumab

Guido Lancman, MD, Dahniel Sastow, BA, Minira Aslanova, MD, Erin Moshier, MS, Hearn Jay Cho, MD PhD, Sundar Jagannath, MD, Deepu Madduri, MD, Samir Parekh, MD, Shambavi Richard, MD, Joshua Richter, MD, Larysa Sanchez, MD, Ajai Chari, MD

Blood (2020) 136 (Supplement 1): 6–7.

https://doi.org/10.1182/blood-2020-140056

Published: 2020

Journal Articles

High Dimensional Immune Profiling in Smoldering Multiple Myeloma Identifies Novel Organizing Features of the Tumor Microenvironment

Hearn Jay Cho, MD PhD, Deepak Perumal, PhD, Adeeb H Rahman, PhD, Seunghee Kim-Schultze, PhD, Jennifer Yesil, Daniel Auclair, Tineke Casneuf, PhD, Homer Adams, III, PhD, Samir Parekh, MD, Sacha Gnjatic, PhD, Nicolas Fernandez, PhD

Blood (2019) 134 (Supplement_1): 4384.

https://doi.org/10.1182/blood-2019-130554

Published: 2019

Journal Articles

Targeting Hypersumoylation in Mantle Cell Lymphoma

Walter Hanel, MD PhD, Liudmyla Tsyba, PhD, Dennis Huszar, PhD, Alex Prouty, Xiaoli Zhang, PhD, JoBeth Helmig-Mason, Msc, Bethany L Mundy-Bosse, PhD, Youssef Youssef, MD, Samir Parekh, MD, Kami J. Maddocks, MD, Robert A Baiocchi, MD PhD, Lapo Alinari, MD PhD

Blood (2019) 134 (Supplement_1): 4060.

https://doi.org/10.1182/blood-2019-127363

Published: 2019

Journal Articles

ADAR1 Drives Disease Progression in Multiple Myeloma By Acting Both As an RNA Editor of Specific Transcripts and As a DNA Mutator of Their Cognate Genes

Rafail Nikolaos Tasakis, MSc, BSc, Alessandro Lagana, PhD, Violetta Leshchenko, PhD, David Melnekoff, BS,MS, Itai Beno, PhD, Jonathan J Keats, PhD, Daniel Auclair, Deepu Madduri, MD, Joshua Richter, MD, Ajai Chari, MD, Hearn Jay Cho, MD PhD, Sundar Jagannath, MD, Joel Dudley, PhD, F. Nina Papavasiliou, PhD, Samir Parekh, MD

Blood (2019) 134 (Supplement_1): 3092.

https://doi.org/10.1182/blood-2019-130669

Published: 2019

Journal Articles

Genomic and Immunologic Analysis of Cmaf and Hypermutated Multiple Myeloma: Implications for Immunologic Therapy

Hearn Jay Cho, MD PhD, Deepak Perumal, PhD, Adeeb H Rahman, PhD, Donald Jackson, PhD, Michael Robbins, PhD, Seunghee Kim-Schultze, PhD, Sacha Gnjatic, PhD, Samir Parekh, MD, Jonathan J Keats, PhD, Daniel Auclair

Blood (2019) 134 (Supplement_1): 3093.

https://doi.org/10.1182/blood-2019-131274

Published: 2019

Journal Articles

A Machine Learning Approach Identifies a 30-Gene Model That Predicts Sensitivity to Selinexor in Multiple Myeloma

Alessandro Lagana, PhD, Sherry Bhalla, Adolfo Aleman, Anna Huo-Chang Mei, MS, Violetta Leshchenko, PhD, Yosef Landesman, PhD, David Melnekoff, BS,MS, Itai Beno, PhD, Deepu Madduri, MD, Joshua R Richter, MD, Ajai Chari, MD, Hearn Jay Cho, MD PhD, Sundar Jagannath, MD, Joel Dudley, PhD, Samir Parekh, MD

Blood (2019) 134 (Supplement_1): 3101.

https://doi.org/10.1182/blood-2019-130753

Published: 2019

Journal Articles

Outcomes in Multiple Myeloma Patients Progressing on Lenalidomide Maintenance

Larysa Sanchez, MD, Erin Moshier, MS, Alexander Coltoff, MD, Ali Mustafa, MD, Darren Pan, MD BS, Hearn Jay Cho, MD PhD, Sundar Jagannath, MD, Deepu Madduri, MD, Samir Parekh, MD, Shambavi Richard, MD, Joshua Richter, MD, Ajai Chari, MD

Blood (2019) 134 (Supplement_1): 1779.

https://doi.org/10.1182/blood-2019-128441

Published: 2019

Journal Articles

Multidimensional Single Cell Analysis Shows Increased T/NK Cell Subsets in Both Blood and Bone Marrow of Iberdomide (CC-220) Treated Relapsed/Refractory Multiple Myeloma Patients

Michael Amatangelo, Oliver Van Oekelen, MD MSc, Adeeb H Rahman, PhD, Alessandro Lagana, PhD, Sarah Gooding, FRCPath,MRCP,MBBChir, Hervé Avet-Loiseau, MD PhD, Udo Oppermann, PhD, William E Pierceall, PhD, Anjan Thakurta, Samir Parekh, MD

Blood (2019) 134 (Supplement_1): 1775.

https://doi.org/10.1182/blood-2019-126146

Published: 2019

Journal Articles

Minimal Residual Disease (MRD) Assessment in the ECOG1411 Randomized Phase 2 Trial of Front-Line Bendamustine-Rituximab (BR)-Based Induction Followed By Rituximab (R) ± Lenalidomide (L) Consolidation for Mantle Cell Lymphoma (MCL)

Mitchell Smith, MD PhD, Opeyemi Jegede, PhD, Samir Parekh, MD, Curtis A. Hanson, MD, Peter Martin, FRCPC, MD MS, Brian G. Till, MD, Michael Crump, MD FRCPC, John P. Leonard, MD, Jonathan W. Friedberg, MD, Brad S. Kahl, MD, Thomas E. Witzig, MD

Blood (2019) 134 (Supplement_1): 751.

https://doi.org/10.1182/blood-2019-129323

Published: 2019

Journal Articles

MAGE-A3 Promotes Chemotherapy Resistance and Proliferation in Multiple Myeloma through Regulation of BIM and p21 Cip1

Hearn Jay Cho, MD, Anna Huo-Chang Mei, MS, Kaity Tung, BS, Jessie Han, Deepak Perumal, PhD, Jonathan J Keats, PhD, Daniel Auclair, PhD, Ajai Chari, MD, Sundar Jagannath, MD, Samir Parekh, MD, Alessandro Lagana, PhD

Blood (2018) 132 (Supplement 1): 4464.

https://doi.org/10.1182/blood-2018-99-118692

Published: 2018

Journal Articles

Increased HLA-E Expression Correlates with Early Relapse in Multiple Myeloma

Blood (2018) 132 (Supplement 1): 59.

https://doi.org/10.1182/blood-2018-99-116828

Published: 2018

Journal Articles

E2F1 Is a Biomarker of Selinexor Resistance in Relapsed/Refractory Multiple Myeloma Patients

Alessandro Lagana, PhD, Seongjee Park, Donna Edwards, Violetta Leshchenko, PhD, Marsha Crochiere, Yosef Landesman, PhD, David Melnekoff, BS,MS, Itai Beno, PhD, Deepak Perumal, PhD, Deepu Madduri, MD, Joshua Richter, Ajai Chari, MD, Hearn Jay Cho, MD, Bart Barlogie, MD PhD, Sundar Jagannath, MD, Joel Dudley, PhD, Samir Parekh, MD

Blood (2018) 132 (Supplement 1): 3216.

https://doi.org/10.1182/blood-2018-99-116500

Published: 2018

Journal Articles

Development of a Neoantigen Prediction Tool for Patient Stratification in Immuno-Oncology Trials

Daniel Duncan, MD, Venkata Thodima, PhD, Jack Yen, MS, Samir Parekh, MD, Alessandro Lagana, PhD, Rita Shaknovich, MD PhD

Blood (2018) 132 (Supplement 1): 2215.

https://doi.org/10.1182/blood-2018-99-119094

Published: 2018

Journal Articles

Phase 1 Study of Elotuzumab and Peripheral Blood Mononuclear Cell Reconstitution in Combination with Autologous Stem Cell Transplantation and Lenalidomide Maintenance for Multiple Myeloma

Keren Osman, MD, Ajai Chari, Samir Parekh, MD, Adolfo Aleman, Jessica Caro, MD, Gillian Morgan, RN, Erika Florendo, NP, Elaine Chan, Gina Strumolo, Katarzyna Zarychta, Lisa La, BS, MS, John Mandeli, PhD, Seunghee Kim-Schultze, PhD, Sacha Gnjatic, PhD, Sundar Jagannath, MD, Hearn Jay Cho, MD PhD

Blood (2017) 130 (Supplement 1): 3282.

https://doi.org/10.1182/blood.V130.Suppl_1.3282.3282

Published: 2017

Journal Articles

Single-Cell RNA Sequencing Reveals Distinct Transcriptomic Profiles of Multiple Myeloma with Implications for Personalized Medicine

David Melnekoff, BS, MSc, Alessandro Lagana, PhD, Wissam Hamou, PhD, Kimaada Allette, BS, Itai Beno, PhD, Violetta Leshchenko, PhD, Deepak Perumal, PhD, Deepu Madduri, MD, Ajai Chari, MD, Hearn Jay Cho, MD PhD, Bart Barlogie, MD PhD, Sundar Jagannath, MD, Joel Dudley, PhD, Robert Sebra, PhD, Samir Parekh, MD

Blood (2017) 130 (Supplement 1): 62.

https://doi.org/10.1182/blood.V130.Suppl_1.62.62

Published: 2017

Journal Articles

Clonal Evolution in Newly Diagnosed Multiple Myeloma Patients: A Follow-up Study from the Mmrf Commpass Genomics Project

Alessandro Lagana, PhD, David Melnekoff, BS, MSc, Itai Beno, PhD, Violetta Leshchenko, PhD, Deepak Perumal, PhD, Jonathan J. Keats, PhD, Mary DeRome, MS, Jennifer Yesil, MS, Daniel Auclair, PhD, Deepu Madduri, MD, Ajai Chari, MD, Hearn Jay Cho, MD PhD, Bart Barlogie, MD PhD, Sundar Jagannath, MD, Joel Dudley, PhD, Samir Parekh, MD

Blood (2017) 130 (Supplement 1): 325.

https://doi.org/10.1182/blood.V130.Suppl_1.325.325

Published: 2017

Journal Articles

Risk-Adapted Therapy in Adults with Burkitt Lymphoma: Results of NCI 9177, a Multicenter Prospective Phase II Study of DA-EPOCH-R

Blood (2017) 130 (Supplement 1): 188.

https://doi.org/10.1182/blood.V130.Suppl_1.188.188

Published: 2017

Journal Articles

MAGE-a Inhibits Apoptosis in Multiple Myeloma through Regulation of Bim and PUMA

Hearn Jay Cho, MD PhD, Anna Huo-Chang Mei, MS, Jami Fukui, MD, Kaity Tung, BS, Deepak Perumal, PhD, Violetta Leshchenko, PhD, Alessandro Lagana, PhD, Seunghee Kim-Schultze, PhD, Ajai Chari, Sundar Jagannath, MD, Samir Parekh, MD

Blood (2017) 130 (Supplement 1): 4332.

https://doi.org/10.1182/blood.V130.Suppl_1.4332.4332

Published: 2017

NARROW

Aberrant Cell Cycle Programming Confers Rapid Lethality in the EuSOX11+ CCND1 MCL Mouse Model

28-Day Metronomic Therapy for Relapsed Refractory Multiple Myeloma

Effect of Intravenous Immunoglobulin on Infections in Multiple Myeloma (MM) Patients Receiving Daratumumab

High Dimensional Immune Profiling in Smoldering Multiple Myeloma Identifies Novel Organizing Features of the Tumor Microenvironment

Targeting Hypersumoylation in Mantle Cell Lymphoma

ADAR1 Drives Disease Progression in Multiple Myeloma By Acting Both As an RNA Editor of Specific Transcripts and As a DNA Mutator of Their Cognate Genes

Genomic and Immunologic Analysis of Cmaf and Hypermutated Multiple Myeloma: Implications for Immunologic Therapy

A Machine Learning Approach Identifies a 30-Gene Model That Predicts Sensitivity to Selinexor in Multiple Myeloma

Outcomes in Multiple Myeloma Patients Progressing on Lenalidomide Maintenance

Multidimensional Single Cell Analysis Shows Increased T/NK Cell Subsets in Both Blood and Bone Marrow of Iberdomide (CC-220) Treated Relapsed/Refractory Multiple Myeloma Patients

Minimal Residual Disease (MRD) Assessment in the ECOG1411 Randomized Phase 2 Trial of Front-Line Bendamustine-Rituximab (BR)-Based Induction Followed By Rituximab (R) ± Lenalidomide (L) Consolidation for Mantle Cell Lymphoma (MCL)

MAGE-A3 Promotes Chemotherapy Resistance and Proliferation in Multiple Myeloma through Regulation of BIM and p21 Cip1

Increased HLA-E Expression Correlates with Early Relapse in Multiple Myeloma

E2F1 Is a Biomarker of Selinexor Resistance in Relapsed/Refractory Multiple Myeloma Patients

Development of a Neoantigen Prediction Tool for Patient Stratification in Immuno-Oncology Trials

Phase 1 Study of Elotuzumab and Peripheral Blood Mononuclear Cell Reconstitution in Combination with Autologous Stem Cell Transplantation and Lenalidomide Maintenance for Multiple Myeloma

Single-Cell RNA Sequencing Reveals Distinct Transcriptomic Profiles of Multiple Myeloma with Implications for Personalized Medicine

Clonal Evolution in Newly Diagnosed Multiple Myeloma Patients: A Follow-up Study from the Mmrf Commpass Genomics Project

Risk-Adapted Therapy in Adults with Burkitt Lymphoma: Results of NCI 9177, a Multicenter Prospective Phase II Study of DA-EPOCH-R

MAGE-a Inhibits Apoptosis in Multiple Myeloma through Regulation of Bim and PUMA

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only